Immunome Inc. 4

Immunome Inc. Chief Medical Officer Robert Lechleider received an award of 54,000 RSU shares of common stock and 108,000 stock options at a $22.01 exercise price on July 23, 2026.

On July 23, 2026, Immunome Inc. Chief Medical Officer Robert Lechleider received equity-based compensation consisting of 54,000 shares of common stock in the form of restricted stock units (RSUs) and an employee stock option grant for 108,000 shares at an exercise price of $22.01 per share, with no cash paid and no open-market buying or selling involved. The RSUs, which represent the right to receive common shares upon settlement, vest annually over four years at 25% per year, subject to continued service, while the options vest 25% on July 23, 2027 and the remaining 75% in equal monthly installments over the subsequent 36 months, also contingent on continued employment. After these awards, Lechleider beneficially owns 69,805 shares of common stock directly, and holds unexercised options for 108,000 shares; using the option exercise price as a proxy for the current stock price, his direct common stock holdings are valued at approximately $1.54 million and the option grant represents additional potential value of about $2.38 million if fully vested and in-the-money.

Filing Facts

CIK

1472012

Ticker

IMNM

Form

4

Source Type

fda

Accession

0001997584-26-000006

Alert Tier

5